Shuming HU, the founder of Synvoma, is the helmsman of national high-tech enterprises and specialized, refined, unique, and innovative enterprises. He has been deeply involved in the fields of digital heart and virtual patient computing, leading the construction of the first disease-specific digital heart drug safety evaluation platform in China that surpasses the FDA CiPA2.0 standard. Hu Shuming led his team to break through the core limitations of the existing FDA CiPA2.0 system, which is based on "healthy adult cardiomyocytes", and pioneered a drug risk calculation model based on real disease cell phenotypes such as heart failure, long QT, and ischemia globally. This model can produce golden indicators that healthy cells cannot provide at all: disease-specific ΔAPD90 prolongation rate, calcium overload index, maximum depolarization rate attenuation, and trigger activity threshold concentration, filling a global gap. The team has completed the replication of 28 FDA reference drug systems and is advancing the application for dual certification of FDA MMF and DDT. He is committed to integrating virtual patient NAMs technology throughout the entire process from new drug development to scientific regulation, promoting the reconstruction of the next-generation CiPA2.0 standard, and ensuring that every decision related to heart safety has a digital basis.